( ARTG ) MAVIRET is indicated for the treatment of adult and paediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. This includes patients with HCV GT1 infection who were previously treated with either a regimen of an NS5A inhibitor or with an NS3/4A protease inhibi

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-

OTC

HealthdirectFree Australian health advice you can count on.

INN: GLÉCAPRÉVIR

Available in:

🇬🇧🇫🇷

Form

—

Dosage

—

Route

—

Storage

—

About This Product

Manufacturer

ABBVIE DEUTSCHLAND (ALLEMAGNE) (FR)

Source

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.